Latest United States Startup Funding Rounds
Startup funding in United States: recent rounds, the companies behind them and their participating investors.
- Rounds
- 756 Jul 27 – Oct 24, 2026
- Disclosed funding
- $68.7B 610 disclosed amounts
- Median round
- $25M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| B BleeCompany profile Blee gives legal, compliance and marketing teams an AI-assisted system to review promotional content against their rules before publication and monitor websites, social media and partner channels afterward. Blee gives legal, compliance and marketing teams an AI-assisted system to review promotional content against their rules before publication and monitor websites, social media and partner channels afterward. | $20M | Series A | Enterprise software | United States | Investors | |
| BE Bluecore EnergyCompany profile Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure | $40M | Seed — additional capital within USD50m financingSeed | Climate tech | United States | Investors Silverton PartnersLeadAct One Ventures +23Animal CapitalBAG CollectiveBorusan VenturesCapital FactoryCollab CapitalFortson VCHarlem CapitalHartBeat VenturesJoel EmbiidLMnT VenturesMaC VenturesMalik MonkMarkham Valley VenturesPrecursor VenturesRackhouse Venture CapitalScribble VenturesShare VenturesSlauson & Co.Symphony VenturesTaijuan WalkerVanderbilt UniversityVisible HandsX& | |
| MB Moonwalk BiosciencesCompany profile Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. | $70M | Series B | Biotech | United States | Investors | |
| F Fab2Company profile Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. | $500M | Series A | Hardware | United States | Investors | |
| BB BrainChild BioCompany profile BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. | $116M | Series A | Biotech | United States | Investors Undisclosed | |
| TI Tokoshie, Inc.Company profile The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models. The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models. | Undisclosed | FundingUndisclosed | AI | United States | Investors | |
| P ParlayXCompany profile ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. | $1.3M | Pre-SeedPre-seed | Fintech | United States | Investors | |
| GL Gimlet LabsCompany profile Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. | $300M | Series B | AI | United States | Investors | |
| CB Cloverleaf BioCompany profile Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. | $33M | Seed | Biotech | United States | Investors | |
| A AntiochCompany profile Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. | $32M | Series A | AI | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 27, 2026
- 1Y Combinator (YC)
Tractian, Blacksmith, Greptile
55rounds3led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
42rounds16led - 3Khosla Ventures
Arda Industries, Tolan
25rounds6led - 4Sequoia Capital
Warhound, Whop, Blacksmith
23rounds7led - 5Alumni Ventures
Maxinsights, Daytona, Chariot Claims
21rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.